Novel Agent for Chronic GVHD Wins FDA Approval

Published Date: 19 Aug 2024

Axatilimab achieved a 75% response rate in patients with previously treated chronic GVHD

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.

2.

In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.

3.

Recurrent UTIs impact eGFR in children with vesicoureteral reflux

4.

Month-Long Wait Times Caused by US Physician Shortage.

5.

Pharyngoesophageal junction cancer is not a good candidate for endoscopically assisted transoral surgery.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot